share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC ·  Aug 27 04:46
Summary by Futu AI
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated